Ongoing | Cancer Accelerated Approvals
The FDA has compiled the status of postmarketing confirmatory trials for cancer drugs granted accelerated approval, including sevabertinib for HER2-mutated NSCLC (trial SOHO-02) and camizestrant for HR+/HER2- ESR1-mutated breast cancer.